Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription 10.06.2024 1 Actas Urol Esp (Engl Ed) 1 Anal Chem 1 Ann Oncol 1 Arch Esp Urol 1 Asia Pac J Oncol Nurs 1 Asian J Surg 1 Biomed Pharmacother 1 BMJ Case Rep 1 Cancer Lett 1 Cancer Manag Res 1 Cancer Prev Res (Phila) 1 Cell Cycle 5 Clin Genitourin Cancer 1 Clin Lab Med 1 Clin Med Insights Oncol 1 Curr Oncol Rep 1 Curr Opin Urol 1 Eur J Nutr 1 Fr J Urol 2 Front Oncol 1 Front Public Health 1 Heliyon 1 Int Immunopharmacol 1 Int J Oncol 1 Int J Surg 5 Int J Urol 1 Int Urogynecol J 1 J Cell Mol Med 1 J Exp Med 1 J Magn Reson Imaging 1 Minerva Urol Nephrol 1 Mol Biotechnol 1 Nat Commun 1 Nat Med 1 Oncol Res 1 Pathol Res Pract 1 Sci Rep 1 Transl Oncol 1 Urol Int

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Actas Urol Esp (Engl Ed)

1. MUNIZ SUAREZ L, Subira Rios J, Gayarre Abril P, Montero Martoran A, et al
   Influence of laparoscopic surgery on the outcomes of radical cystectomy within a multimodal rehabilitation protocol.
   Actas Urol Esp (Engl Ed). 2024;48:364-370.
   PubMed         Abstract available
   
   

   
   Anal Chem

2. WU N, Wong KY, Yu X, Zhao JW, et al
   Multispectral 3D DNA Machine Combined with Multimodal Machine Learning for Noninvasive Precise Diagnosis of Bladder Cancer.
   Anal Chem. 2024 Jun 6. doi: 10.1021/acs.analchem.4c01749.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. POWLES T, Bellmunt J, Comperat E, De Santis M, et al
   ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
   Ann Oncol. 2024;35:485-490.
   PubMed        
   
   

   
   Arch Esp Urol

4. TIAN F, Wei Y, Wang T, Yuan X, et al
   Letter to the Editor Re: Treatment Progress of Compound Kushen Injection and Gemcitabine in Postoperative Patients with Bladder Cancer and Selection of Drug Delivery Mode.
   Arch Esp Urol. 2024;77:453-454.
   PubMed        
   
   

   
   Asia Pac J Oncol Nurs

5. KIM SH, Ryu E, Jeong BC
   Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder.
   Asia Pac J Oncol Nurs. 2024;11:100490.
   PubMed         Abstract available
   
   

   
   Asian J Surg

6. YE L, Lu L, Feng D, Ke M, et al
   DMRT1 could serve as a prognostic biomarker for bladder cancer patients.
   Asian J Surg. 2024 Jun 3:S1015-9584(24)01111.
   PubMed        
   
   

   
   Biomed Pharmacother

7. WU L, Hu Z, Song XF, Liao YJ, et al
   Targeting Nrf2 signaling pathways in the role of bladder cancer: From signal network to targeted therapy.
   Biomed Pharmacother. 2024;176:116829.
   PubMed         Abstract available
   
   

   
   BMJ Case Rep

8. VARRIOR AR, Thakkar H, Kale S
   Radiological features of multifocal embryonal rhabdomyosarcoma affecting the vagina and the urinary bladder in a pediatric patient.
   BMJ Case Rep. 2024;17:e259549.
   PubMed         Abstract available
   
   

   
   Cancer Lett

9. SHEN C, Liu J, Xie F, Yu Y, et al
   N6-Methyladenosine enhances the translation of ENO1 to promote the progression of bladder cancer by inhibiting PCNA ubiquitination.
   Cancer Lett. 2024;595:217002.
   PubMed         Abstract available
   
   

   
   Cancer Manag Res

10. ZHANG X, Ma L
    Predictive Value of the Total Bilirubin and CA50 Screened Based on Machine Learning for Recurrence of Bladder Cancer Patients.
    Cancer Manag Res. 2024;16:537-546.
    PubMed         Abstract available
    
    

    
    Cancer Prev Res (Phila)

11. JIN F, Thaiparambil J, Donepudi SR, Vantaku V, et al
    Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
    Cancer Prev Res (Phila). 2024;17:281.
    PubMed        
    
    

    
    Cell Cycle

12. ZHOU W, Yang Y, Wang W, Yang C, et al
    Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer progression by competing with miR-145-5p.
    Cell Cycle. 2024 Jun 6:1-17. doi: 10.1080/15384101.2024.2353554.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

13. NARITA C, Urabe F, Fukuokaya W, Iwatani K, et al
    Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
    Clin Genitourin Cancer. 2024;22:102082.
    PubMed         Abstract available
    
    
14. VLACHOU E, Mamtani R, Hahn NM, Iii BJ, et al
    Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin.
    Clin Genitourin Cancer. 2024;22:102090.
    PubMed         Abstract available
    
    
15. CHEN J, Wang M, Qi X, Long H, et al
    RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China.
    Clin Genitourin Cancer. 2024;22:102093.
    PubMed         Abstract available
    
    
16. FLEMING S, Gifkins D, Resnick HE, Shalaby W, et al
    Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:102054.
    PubMed         Abstract available
    
    
17. TAPIA JC, Bosma F, Gavira J, Sanchez S, et al
    Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
    Clin Genitourin Cancer. 2024;22:102047.
    PubMed         Abstract available
    
    

    
    Clin Lab Med

18. AL-AHMADIE H, Netto GJ
    Molecular Pathology of Urothelial Carcinoma.
    Clin Lab Med. 2024;44:181-198.
    PubMed         Abstract available
    
    

    
    Clin Med Insights Oncol

19. BALLI S, Bolek H, Urun Y
    Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.
    Clin Med Insights Oncol. 2024;18:11795549241257238.
    PubMed         Abstract available
    
    

    
    Curr Oncol Rep

20. LINSCOTT JA, Miyagi H, Murthy PB, Yao S, et al
    From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.
    Curr Oncol Rep. 2024 Jun 5. doi: 10.1007/s11912-024-01555.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

21. FAZEKAS T, Miszczyk M, Matsukawa A, Nyirady P, et al
    Defining oligometastatic state in uro-oncological cancers.
    Curr Opin Urol. 2024;34:261-265.
    PubMed         Abstract available
    
    

    
    Eur J Nutr

22. BOOT IWA, Wesselius A, Jochems SHJ, Yu EYW, et al
    Fruits and vegetables intake and bladder cancer risk: a pooled analysis from 11 case-control studies in the BLadder cancer Epidemiology and Nutritional Determinants (BLEND) consortium.
    Eur J Nutr. 2024 Jun 5. doi: 10.1007/s00394-024-03436.
    PubMed         Abstract available
    
    

    
    Fr J Urol

23. BLACHIER M, Ye H, Long JA, Descotes JL, et al
    Interest of the POSPOM score in estimating postoperative complication risk after radical cystectomy.
    Fr J Urol. 2024;34:102610.
    PubMed         Abstract available
    
    

    
    Front Oncol

24. GALBIATI S, Bettiga A, Colciago G, Senti C, et al
    The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer progression.
    Front Oncol. 2024;14:1325157.
    PubMed         Abstract available
    
    
25. ZHANG Y, Guo X, Zhang Y, Wei J, et al
    A preliminary investigation of precise visualization, localization, and resection of pelvic lymph nodes in bladder cancer by using indocyanine green fluorescence-guided approach through intracutaneous dye injection into the lower limbs and perineum.
    Front Oncol. 2024;14:1384268.
    PubMed         Abstract available
    
    

    
    Front Public Health

26. BABADI F, Ahmadi A, Sarkarian M, Cheraghi M, et al
    Relationship between oral health literacy and oral health-related quality of life in patients with bladder cancer.
    Front Public Health. 2024;12:1385443.
    PubMed         Abstract available
    
    

    
    Heliyon

27. HUANG Y, Chen L, Zou Y, Yu H, et al
    Bibliometric insights into drug resistance in bladder cancer: Two decades of progress (1999-2022).
    Heliyon. 2024;10:e31587.
    PubMed         Abstract available
    
    

    
    Int Immunopharmacol

28. ZHANG J, Huang Y, Tan X, Wang Z, et al
    Integrated analysis of multiple transcriptomic approaches and machine learning integration algorithms reveals high endothelial venules as a prognostic immune-related biomarker in bladder cancer.
    Int Immunopharmacol. 2024;136:112184.
    PubMed         Abstract available
    
    

    
    Int J Oncol

29. THI TN, Thanh HD, Nguyen VT, Kwon SY, et al
    Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9.
    Int J Oncol. 2024;65:71.
    PubMed         Abstract available
    
    

    
    Int J Surg

30. WANG Z, Zhang G, Liu X, Tan G, et al
    A commentary on "Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T cell - Fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning" (Int J Surg. 2024 May 17.).
    Int J Surg. 2024 Jun 4. doi: 10.1097/JS9.0000000000001769.
    PubMed        
    
    

    
    Int J Urol

31. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
    Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?
    Int J Urol. 2024;31:628-636.
    PubMed         Abstract available
    
    
32. UEMURA K, Ito H, Jikuya R, Kondo T, et al
    Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Int J Urol. 2024;31:678-684.
    PubMed         Abstract available
    
    
33. MIKI J, Fukuokaya W, Taoka R, Saito R, et al
    Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
    PubMed         Abstract available
    
    
34. FU H, Hillman E, Talluri S, Liang L, et al
    Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic-assisted cystectomy with urinary diversion.
    Int J Urol. 2024;31:646-652.
    PubMed         Abstract available
    
    
35. HARA T, Matsushita Y, Harada K, Fujimoto N, et al
    Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
    Int J Urol. 2024;31:696-698.
    PubMed        
    
    

    
    Int Urogynecol J

36. CARBONE L, Webber V, Rothenberger R, Lenger SM, et al
    Robotic Vaginal Hernia Repair for Recurrent Vaginal Prolapse Status Post-Radical Cystectomy with an Indiana Pouch.
    Int Urogynecol J. 2024;35:1097-1099.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

37. LI H, Ma H, Ma J, Qin F, et al
    Unveiling the role of RAC3 in the growth and invasion of cisplatin-resistant bladder cancer cells.
    J Cell Mol Med. 2024;28:e18473.
    PubMed         Abstract available
    
    

    
    J Exp Med

38. TRAN MA, Youssef D, Shroff S, Chowhan D, et al
    Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment.
    J Exp Med. 2024;221:e20240045.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

39. KONG L, Li H, Cai Q, Cao W, et al
    Amide Proton Transfer-Weighted Imaging in Assessing the Aggressive and Proliferative Potential of Bladder Cancer.
    J Magn Reson Imaging. 2024 Jun 1. doi: 10.1002/jmri.29464.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

40. CICIONE A, Lombardo R, Nacchia A, Franco A, et al
    No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomiz
    Minerva Urol Nephrol. 2024 Jun 5. doi: 10.23736/S2724-6051.24.05777.
    PubMed         Abstract available
    
    

    
    Mol Biotechnol

41. LI J, Feng S, Wang X, Zhang B, et al
    Exploring the Targets and Molecular Mechanisms of Curcumin for the Treatment of Bladder Cancer Based on Network Pharmacology, Molecular Docking and Molecular Dynamics.
    Mol Biotechnol. 2024 Jun 1. doi: 10.1007/s12033-024-01190.
    PubMed         Abstract available
    
    

    
    Nat Commun

42. JUAN RAMON A, Parmar C, Carrasco-Zevallos OM, Csiszer C, et al
    Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial.
    Nat Commun. 2024;15:4690.
    PubMed         Abstract available
    
    

    
    Nat Med

43. LI R, Shah PH, Stewart TF, Nam JK, et al
    Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
    Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025.
    PubMed         Abstract available
    
    

    
    Oncol Res

44. KIM H, Cho U, Hong SH, Park HS, et al
    New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
    Oncol Res. 2024;32:1021-1030.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

45. YAN B, Luo P, Qiu H, Wang J, et al
    PC4 promotes bladder cancer progression and stemness by directly interacting with Sp1 to transcriptionally activate the Wnt5a/beta-catenin pathway.
    Pathol Res Pract. 2024;259:155369.
    PubMed         Abstract available
    
    

    
    Sci Rep

46. ZHANG T, Zhu J, Li Z, Zhao Y, et al
    The UF-5000 Atyp.C parameter is an independent risk factor for bladder cancer.
    Sci Rep. 2024;14:12659.
    PubMed         Abstract available
    
    

    
    Transl Oncol

47. ZUCCA LER, Laus AC, Sorroche BP, Paro E, et al
    Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer.
    Transl Oncol. 2024;46:102003.
    PubMed         Abstract available
    
    

    
    Urol Int

48. OZCAN L, Polat EC, Baran C, Boylu A, et al
    Systemic Inflammatory Index: A Promising Non-Invasive Marker for the Prediction of Response to Neoadjuvant Chemotherapy prior to Cystectomy.
    Urol Int. 2024;108:226-233.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.